VIE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-21), Viela Bio's share price is $53.01. Viela Bio's Book Value per Share for the quarter that ended in Dec. 2020 was $6.85. Hence, Viela Bio's PB Ratio of today is 7.74.
The historical rank and industry rank for Viela Bio's PB Ratio or its related term are showing as below:
During the past 3 years, Viela Bio's highest PB Ratio was 9.70. The lowest was 3.62. And the median was 5.30.
During the past 12 months, Viela Bio's average Book Value Per Share Growth Rate was -2.20% per year.
The historical data trend for Viela Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viela Bio Annual Data | |||||||
Trend | Dec18 | Dec19 | Dec20 | ||||
PB Ratio | - | 3.88 | 5.25 |
Viela Bio Quarterly Data | ||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | |
PB Ratio | Get a 7-Day Free Trial | 3.88 | 6.12 | 5.39 | 3.79 | 5.25 |
For the Biotechnology subindustry, Viela Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viela Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Viela Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Viela Bio's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Dec. 2020) |
= | 53.01 | / | 6.847 | |
= | 7.74 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Viela Bio (NAS:VIE) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Viela Bio's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Chris Nolet | director | C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Rachelle Suzanne Jacques | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Edward Hu | director | 10975 TORREY PINES ROAD, LA JOLLA CA 92037 |
Boyu Capital General Partner Iii, L.p. | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boyu Capital General Partner Iii, Ltd. | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boyu Capital Group Holdings Ltd. | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Xyxy Holdings Ltd. | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boyu Capital Investment Management Ltd | 10 percent owner | SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boundless Meadow Ltd | 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Xiaomeng Tong | director, 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Yanling Cao | director, 10 percent owner | SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000 |
Boyu Capital Fund Iii, L.p. | 10 percent owner | C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104 |
Boyu Capital Opportunities Master Fund | 10 percent owner | CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008 |
Zhengbin Yao | director, officer: Chief Executive Officer | 10301 STELLA LINK ROAD, HOUSTON TX 77025 |
William Ragatz | officer: VP, Head of Commercial | C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 06-11-2020
By Marketwired Marketwired • 05-14-2020
By Marketwired Marketwired • 11-02-2020
By Marketwired Marketwired • 11-06-2020
By Marketwired Marketwired • 02-25-2021
By Marketwired Marketwired • 03-26-2020
By Marketwired Marketwired • 03-18-2020
By PRNewswire PRNewswire • 02-13-2021
By GlobeNewswire GlobeNewswire • 05-28-2020
By Marketwired Marketwired • 02-01-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.